Mavacamten monotherapy in obstructive hypertrophic cardiomyopathy: An integrated analysis of phase 3 clinical trials.
Iacopo Olivotto, Pablo Garcia-Pavia, Zhuang Tian et al.
✦ AI-curated · Sources linked
In 30 seconds
This integrated analysis pooled patients from four phase 3 trials of mavacamten for symptomatic obstructive hypertrophic cardiomyopathy, grouping them by background therapy at treatment initiation. Mavacamten monotherapy was associated with improvements in left ventricular outflow tract gradients and symptoms. Descriptive comparisons suggested broadly similar efficacy trends and adverse event rates with monotherapy and mavacamten combined with beta-blockers or calcium-channel blockers. Across treatment groups, reductions in left ventricular ejection fraction from baseline to week 128 were ≤8.8%. The findings support improvement with monotherapy but do not establish comparative equivalence.
Key findings
- Mavacamten monotherapy was associated with improvements in left ventricular outflow tract gradients and symptoms.
- Descriptive comparisons suggested broadly similar efficacy trends and adverse event rates across monotherapy and background beta-blocker or calcium-channel blocker groups.
- Left ventricular ejection fraction reductions from baseline to week 128 were ≤8.8% across treatment groups.
Why it matters
Many patients in the phase 3 studies received mavacamten alongside other HCM pharmacological therapies. These pooled findings indicate that improvement was also observed among patients receiving mavacamten alone, while offering descriptive context on outcomes with background beta-blockers or calcium-channel blockers. This may help inform understanding of mavacamten outcomes across differing medication regimens.
What to keep in mind
The analysis pooled trial participants by background therapy use, and comparisons were descriptive; it does not establish that monotherapy and combination therapy are equivalent.